Entity

Time filter

Source Type


Ning S.,Central South University | Huang Q.,Central South University | Sun X.,Central South University | Li C.,CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co. | And 4 more authors.
Soft Matter | Year: 2011

Liposomes have been widely used as promising drug delivery systems. The stabilization of liposomes however remains challenging, especially when surface binding properties are involved. In this work, we reported carboxymethyl dextran-coated liposomes (CMD-LIPs), in an attempt to improve their stability, surface binding and release properties. Firstly, we introduced hydrophobic oleyl groups onto CMD, and then used the amphiphilic CMD, phosphatidylcholine and cholesterol to prepare the CMD-LIPs. Surface plasmon resonance measurements confirmed that CMD-LIPs inhibited non-specific protein adsorption and exhibited active targeting when coupling ligands to the liposomal surface. Moreover, doxorubicin (DOX)-loaded CMD-LIPs displayed a sustained and pH-responsive drug release profile. MTT assay revealed that the cytotoxicity of DOX-loaded CMD-LIPs on HeLa cells was time- and concentration- dependent. Additionally, the DOX-loaded CMD-LIPs were highly stable in serum media and against dilution, long-term storage and lyophilization. © 2011 The Royal Society of Chemistry. Source


Patent
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co. | Date: 2011-12-22

Provided is a crystalline form E of ertapenem sodium. Further provided is a method for preparing a crystalline form E of ertapenem sodium, characterized by using an aqueous ertapenem sodium solution at a low concentration as a raw material. The crystalline form E can be easily filtered and dried, the properties in the drying process are stable, and the purity of the crystal is high and can be up to 98.5% or higher.


Patent
University of Sichuan and Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co. | Date: 2011-05-26

The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.


Patent
Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co. | Date: 2015-07-02

Purified therapeutic nanoparticles are provided herein. Such nanoparticles comprise an active pharmaceutical ingredient and human serum albumin, wherein the weight ratio of human serum albumin to the active ingredient in the therapeutic nanoparticles is from 0.01:1 to 1:1, and wherein the nanoparticles are substantially free of free human serum albumin that is not incorporated in the nanoparticles. The present disclosure also provides pharmaceutical compositions that comprise the purified therapeutic nanoparticles and are also substantially free of free human serum albumin. Methods for preparing and using the purified therapeutic nanoparticles and compositions thereof are also provided.


Patent
Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co. | Date: 2014-09-25

A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase may contain sulfobutyl ether cyclodextrin and an active compound.

Discover hidden collaborations